We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular DNA Tests Identify New Bacterium

By LabMedica International staff writers
Posted on 22 Aug 2011
A new strain of bacteria, causing a tick-borne disease, has been identified through DNA testing. More...


A molecular diagnostic test, combined with DNA sequencing, serology and culture have enabled the identification of a bacterium infecting humans with ehrlichiosis in areas where it was unknown.

A multidisciplinary team centered at the Mayo Clinic (Rochester, MN, USA), extracted DNA from 4,247 blood specimens from residents in 45 US states and tested them by means of a real-time polymerase chain reaction assay (rt-PCR) for bacteria of the family Anaplasmataceae and a nested PCR assay of the groEL gene. Serum and plasma specimens from patients with an atypical groEL PCR product were tested for immunoglobulin G (IgG)-class antibodies reacting to Ehrlichia chaffeensis or Anaplasma phagocytophilum with the use of a commercial indirect immunofluorescence assay (Focus Diagnostics, Cypress, CA, USA).

Of the 1,518 specimens obtained from residents of two US states, 163 (10.7%) were positive for A. phagocytophilum (35 from Wisconsin and 128 from Minnesota), whereas none were positive for E. chaffeensis or E. ewingii. Four residents had positive fluorescence resonance energy transfer PCR assays with a melting temperature that was outside the melting temperature range for E. chaffeensis, E. ewingii, and A. phagocytophilum. This atypical result was not found for the 2,729 specimens collected from the 43 other states. The EhrlichiaAnaplasma real-time groEL PCR assay used in the investigation had the advantage of providing differential detection of Ehrlichia species Wisconsin from E. chaffeensis, E. ewingii, and A. phagocytophilum based on differences in DNA composition of the amplified fragment.

Genetically, the new bacterium bears closest similarity to another species known as E. muris, which infects small rodents and deer in Eastern Europe and Asia. E. muris rarely infects humans, and no cases have been reported in North America. Bobbi S. Pritt, MD, corresponding author of the study, said, "Before this report, human ehrlichiosis was thought to be very rare or absent in Minnesota and Wisconsin. Therefore, physicians might not know to look for Ehrlichia infections at all." Ehrlichia infect and kill white blood cells and may cause fever, body aches, headache, and fatigue. More severe disease may involve multiple organs such as the lungs, kidneys and brain, and require hospitalization, although ehrlichiosis rarely results in human death as it is easily treated. The study was published on August 4, 2011, in the New England Journal of Medicine (NEJM).

Related Links:
Mayo Clinic
Focus Diagnostics




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.